Skip to main content

Table 1 Characteristics of participants with follow-up analysis of GDF-15

From: Circulating levels of GDF15 in patients with myalgic encephalomyelitis/chronic fatigue syndrome

All participants (cases and controls)

Variable

Mean (95% CI) or number (percentage)

Healthy control (n = 40)

Multiple sclerosis (n = 20)

ME/CFS (n = 40)

Age (years)**

42.9 (39.1–46.6)

52.7 (49.8–55.6)

44.1 (40.1–48)

BMI (Kg/m2)

25.9 (24.4–27.4)

24.7 (23–26.4)

25.6 (23.8–27.4)

eGFR (ml/min/1.73 m2)

82.7(79.3–86.1)

75.2 (71–79.5)

79.5 (75.5–83.5)

Female sex

23 (57.5%)

15 (75%)

27 (67.5%)

Current smoking

1 (2.5%)

4 (20%)

4 (10%)

ME/CFS cases

Variable

Mean (95% CI) or number (percentage)

Non-severe cases (n = 24)

Severe cases (n = 16)

Age (years)

47 (42–51.9)

39.8 (33–46.5)

BMI (Kg/m2)*

27.1 (24.9–29.3)

22.9 (20.1–25.7)

eGFR (ml/min/1.73 m2)**

74.7 (69.4–80)

86.5 (81.8–91.2)

Female sex

16 (66.7%)

11 (68.8%)

Current smoking

3 (12.5%)

1 (6.2%)

  1. *P < 0.05, **P < 0.05